Covidien Ltd. announced a $2.6 billion deal in June to acquire ev3 Inc., a leader in the neurointerventional and peripheral vascular interventional markets. The acquisition is expected to close by July 31 when ev3 will join Covidien's $600 million-plus vascular devices business unit. [See Deal] Terms of the deal call for Covidien to pay $22.50 per share, a 19% premium over ev3's previous close of $18.92 on May 28.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?